



EoI No. ICMR/EoI/01/Shigella Vaccine/2024

Invitation for Expression of Interest (EoI)

For

Joint Development & Commercialization of Shigella Vaccine

(Vaccine Candidate)

**ICMR-National Institute for Research in Bacterial Infections
(Indian Council of Medical Research)**

P-33, C.I.T. Road, Scheme-XM, Belehata

P.O. Box 177, Kolkata 700010, INDIA

Ph: +91-33-23633373

Fax: 91-33-23632398

CONTENTS

Sl. No	Section	Page No.
1	Letter of Invitation	3
2	Background	4
3	Objective	4
4	Broad Scope of Work	4
5	Intellectual Property Rights	5
6	Process involved in Partnership/Collaboration	6
7	Publication	6
8	Data Rights	7
9	Details of documents to be furnished	7
10	Rejection Criteria	7
11	Evaluation Methodology	8
12	Pre-Qualification Criteria (PQC)	8
13	Disclaimer	9
14	Arbitration	9
15	Contacts for enquiry	10
16	Expression of Interest (Format – 1)	11
17	Authorization Letter (Format – 2)	13
18	Undertaking with regard to Blacklisting (Format-3)	14
19	Undertaking with regard to Non-Litigation (Format – 4)	15
20	Undertaking with regard to laboratory facility (Format – 5)	16
21	Production Capacity Undertaking (Format-6)	17
22	Schedule A - Technology Details	18

Letter of Invitation

1. Invitation for Expression of Interest

Indian Council of Medical Research ((ICMR), New Delhi invites Expression of Interest (EoI) from the eligible organizations, companies, manufacturers for undertaking **Joint development and commercialization of Shigella Vaccine** useful against blood diarrhea / shigellosis disease.

The EoI document containing the details of qualification criteria, submission details, brief objective & scope of work and evaluation criteria etc. can be downloaded from the ICMR website (<https://www.icmr.gov.in>).

Schedule for the Proponents is as under:

EoI Document Number	EoI No. ICMR/EoI/01/Shigella Vaccine/2024
Date of Publication	Date: 01/07/ 2024
Last date of submission	Date: 31/07/ 2024

Note:

Interested applicants may please send their proposals in a sealed envelope to the following address:

**Director,
ICMR-National Institute for Research in Bacterial Infections
(Indian Council of Medical Research)
P-33, C.I.T. Road, Scheme-XM, Belehata
P.O. Box 177, Kolkata 700010, INDIA
Ph: +91-33-23633373
Fax: 91-33-23632398**

EoI Document No. “**ICMR/EoI/01/Shigella Vaccine/2024**” along with the title of the EOI as “**EoI for Technology Transfer/ Joint Development**” in **Bold** and complete address as above must be clearly mentioned on the sealed envelope.

Only shortlisted firm(s)/organization(s) will be invited to participate in the Request for Proposal (RFP).

ICMR reserves the right to cancel this EoI and/ or invite afresh with or without amendments, without liability or any obligation for such EoI and without assigning any reason. Information provided at this stage is indicative and ICMR reserves the right to amend/add any further details in the EoI, as may be desired by the Competent Authority ICMR and duly notified on its website.

2. **Background**

The Indian Council of Medical Research (ICMR), New Delhi, the apex body in India for the formulation, coordination and promotion of biomedical research, is one of the oldest medical research bodies in the world. The ICMR has always attempted to address the growing demands of scientific advances in biomedical research on the one hand and the need of finding practical solutions to the health problems of the country, on the other.

ICMR- NIRBI Institute, one of the constituent Institutes of the Indian Council of Medical Research (ICMR), located at P33 CIT Road, Beliaghata, Kolkata – 700010, has developed a technology entitled “A Multi-Serotype Outer Membrane Vesicles (MOMV) of shigellae as a novel candidate vaccine and Novel Shigella vaccine formulation and process to prepare thereof (hereinafter) referred to as “**Technology**”.

ICMR is lawfully entitled to enter into any form of **non-exclusive agreements** with eligible manufacturing companies hereinafter referred to as the “**Company**” through a defined agreement for Licensing/Commercialization of Shigella Vaccine, hereinafter referred to as the ‘**Product**’, which shall be governed by ICMR IP Policy, as revised and approved by the Competent Authority.

3. **Objective**

To undertake Joint development and commercialization of the Shigella Vaccine effective/useful against blood diarrhea / shigellosis disease.

4. **Scope of Work**

- i. ICMR is willing to collaborate with eligible organizations, companies, and manufacturers for undertaking Joint development and commercialization of Shigella Vaccine.
- ii. The Company would be granted rights to undertake further development, manufacture, sell, and commercialize the Shigella Vaccine.
- iii. An Agreement following EoI and RFP is proposed to be executed on Non-exclusive basis with single/multiple companies to enable wider outreach of the Shigella Vaccine for societal benefit and public health use. All the related issues shall be governed by ICMR IP Policy, as revised and approved by the Competent Authority.

- iv. ICMR-NIRBI Institute has expertise in various techniques, methods and information relating to aforesaid technology which could be used for the production of Shigella Vaccine.

Role of ICMR:

- i. ICMR-NIRBI Institute will provide expert guidance & technical support for the production of Shigella Vaccine, in all phases. Such technical oversight by ICMR-NIRBI Institute would accelerate the development of the Product and its commercialization.
- ii. ICMR would provide technical support through its team of experienced scientists in study planning, product development, development of study protocol, results/data analysis, outcome assessment, safety & efficacy assessment, product improvement, etc., if deemed fit upon the mutual understanding between ICMR and collaborative company.
- iii. ICMR through its Institutes would provide support and facilitation to conduct the R&D/clinical study of new technology/ product in India through its Affiliates/ Institutes, in collaboration with the company/institutions in a professional and mutually agreed-upon manner and timelines, which will be decided later under the Agreement.
- iv. ICMR would provide technical support in development of technology/ product and will also facilitate the validation, if required, as per the terms & conditions of the Agreement.
- v. ICMR shall have no financial implications unless otherwise specified.

Role of Company

- i. The Company shall have valid provisions to provide all necessary infrastructure/ material/ manpower required for product development/ validation/ scale-up either directly or otherwise.
- ii. The Company shall have provisions to undertake the scale-up as required, manufacturing and commercialization of the Shigella Vaccine, in a set milestone.
- iii. The Company agrees to share the technical data with ICMR and participate in all discussions in a professional and mutually agreed-upon manner.
- iv. The Company agrees to allow authorized personnel/scientist/team of ICMR to visit the designated lab/ production facility as and when required, as envisaged under this EoI and subsequent Agreement.
- v. The Company shall be responsible for obtaining all the regulatory approvals required for commercialization or starting from R&D for product development to its commercialization.

5. Intellectual Property Rights

It is submitted that in case of transfer of Technology, ICMR is the sole owner of the said Technology, including any underlying Intellectual Property(ies) and commercialization rights.

Intellectual Property (IP) shall mean patents, rights to inventions, copyright and related rights, moral rights, rights in designs, rights in trademarks, rights to preserve the confidentiality of information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply for and be granted), divisional, continuations, continuations-in-part, reissues, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world regarding subject matter disclosed in Licensed patents.

ICMR legally possess the rights and authority to retain full or part of the ‘Technology’ by itself or to assign at its discretion full or part of the Technology including any patent(s) or intellectual property rights(s) or the invention(s), and/or ICMR is lawfully entitled to enter into any form of non-exclusive License Agreements with selected companies including transfer of the Technology through suitable Agreement(s).

In case of collaboration between ICMR and the Company for the Joint development of the Technology/ Product, Background Intellectual Property (“BGIP”) shall always remain the sole and Non-exclusive property of the Party generating the BGIP. Any IP, if generated during the course of collaboration, including any improvement thereof, shall be jointly owned by ICMR and the Company. All such provisions related to intellectual property rights shall be governed by ICMR IP Policy, as revised and approved by the Competent Authority.

6. Process involved in Partnership/Collaboration

Interested companies/manufacturers are invited to join hands with ICMR for co-development & commercialization of the Technology/ Product(s). Under this EoI, the manufacturers/companies who are responsive and fulfilling all the technical need will be shortlisted based on their R&D plan, facilities and capabilities. On shortlisting of technically suitable companies, one Request for Proposal (RFP) will be shared with the shortlisted candidates. At the RFP stages, technically suitable candidates will be required to provide complete technical details along with their financial proposal w.r.t. upfront payment and royalty component, in line with the applicable ICMR Guidelines for Technology Transfer and Revenue Sharing, as amended from time to time. Selection of candidates will be decided on the basis of their offers at the RFP stage. Qualified companies/manufacturers will only be contacted for execution of MoA/MoU/Agreement for partnership/collaboration/technology transfer, etc. Subsequent to the execution of the Agreement such companies/manufacturers shall be responsible to pay the Royalty, subject to approval as provided under ICMR Guidelines for Technology Transfer and Revenue Sharing.

7. Publication

- i. In case of Co-development, the Parties shall have equal rights on the manuscripts/scientific publications (joint publication/acknowledgment /other credits as applicable) and in accordance with guidelines of International Committee of Medical Journal Editors (ICMJE.org).

- ii. Support of ICMR must be duly acknowledged in all publications by the Company.
- iii. ICMR Scientists can be given due to advantage of authorships in the publications arising out of Licensing/co-development.

8. Data Rights

- i. Data rights shall be jointly owned by ICMR and Licensee/Co-developer
- ii. Data rights in cases where Artificial Intelligence is involved shall be dealt separately.
- iii. Licensee/ Company to ensure that data is anonymized, kept confidential and strictly abide by the provisions of Information Technology Act, 2000 while dealing with such data

9. Details of documents to be furnished

Proponents are requested to go through all pre-qualification requirements, scope of work for execution & requirements with respect to technical capabilities for submission of interest, subject for verification by ICMR.

Documents to be furnished are as follows:

- i. Declaration - Expression of Interest (Format – 1)
- ii. Authorization Letter (Format – 2)
- iii. Undertaking with regard to Blacklisting (Format-3)
- iv. Undertaking with regard to Non-Litigation (Format – 4)
- v. EoI document with each page duly stamped and signed by the Authorized signatory.
- vi. Undertaking with regard to laboratory facility (Format – 5)
- vii. Production Capacity Undertaking (Format-6)
- viii. Supporting documents, as mentioned in Format-1
- ix. MSME Certificate (if applicable)
- x. Concept note on business plan- A brief concept note on R&D, clinical studies, planning & execution, production, marketing etc. with timeline (not more than 5 pages)
- xi. Any other information which proponent may wish to provide to support the EoI.

ICMR reserves the right to call for any clarifications confined in the broad scope, wherever such a clarification become necessary for proper judgement in evaluation.

10. Rejection Criteria

The application is liable to be rejected if:

- i. The proposal is not submitted as per the requirements indicated in the EoI.
- ii. Not in the prescribed format.
- iii. Not properly stamped and signed.
- iv. Received after the expiry of due date and time.
- v. All relevant supporting documents are not furnished with the Pre-Qualification Criteria (PQC).

- vi. The proposal shall be substantially responsive without any material deviation, failing which the proposal shall be summarily rejected.
- vii. Applications not fulfilling the terms of the document will be summarily rejected.
- viii. Any other non-compliance.

11. Evaluation Methodology

Screening of EoIs shall be carried out as per Pre-Qualification criteria mentioned in the EoI document and based on verification of documents submitted. Only shortlisted proponents shall be provided with RFP.

12. Pre-Qualification Criteria (PQC)

The following will be the minimum Pre-Qualification Criteria (PQC). Responses not meeting the minimum PQC will be summarily rejected and will not be evaluated further:

Sl. No.	Pre-Qualification Criteria (General)	Supporting copy of documents required (All documents must be self-attested by the authorized person of the proponent)
General Criteria		
1	The proponent shall be a legal entity, registered as Institution/Company/ LLP/ Society/ partnership firm/ proprietorship firm under respective acts in India.	Registration of firm/ organization/Company Incorporation Certificate from Registrar of Companies (ROC) /Partnership deed etc. whichever is applicable
2	The proponent must be registered in India with taxation and other administrative authorities.	GST Registration or GST exemption certificate/ PAN Card
3	The proponent should have proven prior experience of manufacturing and/or R&D with manufacturing during the last ten years, either in-house or through agreed collaboration and must have marketed same/similar products in the past with a good track record.	Research paper/Pamphlet / brochure of the product/DCGI License for existing product. Supporting documents for collaboration, if any.
4	The proponent has to be profitable and should not have incurred overall loss in past three (3) years. (Applicable on commercial firms/organizations only)	Certificate from the Chartered Accountant of the Organization/ Audited Balance sheets for last three financial years or Income Tax return.
5	The proponent should have good track record and currently not black-listed/ barred by any Central / State Government	Undertaking on the Letter Head of the Proponent duly signed & stamped by Authorized Signatory (As per format –

	/ Public Sector Undertaking, Govt. of India, (applicable on commercial firms/organizations only).	3).
6	The proponent should have a manufacturing unit in India.	Registration copies/ factory license/ DSIR certificate, if have any.
7	The proponent should not be involved in any major litigation that may have an impact of affecting or compromising the conditions required under this EoI and in the Agreement	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory (As per format – 5)
8	GMP/ quality certification (ISO or approved Indian certification) of manufacturing facility and GLP/ necessary certifications for R & D	Copies of Certificates
Specific Criteria (Based on the nature of the Proposal)		
9.	The proponent should have functional laboratory to carryout R&D for the product development	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory (As per format – 5)
10.	Capacity to produce at least... ..(quantity) per week	Undertaking (As per format – 6)

NOTE- For MSMEs and Start-ups, Start-Up-India, Make-in-India and other relevant guidelines of Government of India shall be applicable

13. Disclaimer

- i. ICMR shall not be responsible for any late receipt of applications for any reasons whatsoever.
- ii. ICMR reserves the right to cancel the call for EoI without assigning any reasons thereof.
- iii. ICMR may relax or waive any of the conditions stipulated in this document as deemed necessary in the best interest of the ICMR without assigning any reasons thereof.
- iv. To include any other item in the Scope of work at any time after consultation with proponents or otherwise.
- v. For International Clients, please note that EoI and other necessary correspondences shall be submitted in English only.

14. Arbitration

That any dispute and/ or any part of the dispute which couldn't be resolved through mutual consultation, the same shall be referred to the sole arbitrator as per the Arbitration & Conciliation Act, 1996 and any amendment thereafter. The Venue and Seat of the arbitration proceedings shall be New Delhi and the courts at New Delhi will have exclusive jurisdiction.

15. Contacts

In case of any clarification required, please contact:

For scientific issues-

Hemanta Koley, M.Sc.; PhD , FAScT
Scientist -F
Division of Bacteriology
ICMR-National Institute for Research in Bacterial Infections
(Indian Council of Medical Research)
P-33, C.I.T. Road, Scheme-XM, Belegkata
P.O. Box 177, Kolkata 700010, INDIA

Cell /WhatsApp : 91 9831031307

Email address : hemantakoley@hotmail.com ; koleyh.niced@gov.in

Format-1

Expression of Interest

(To be submitted on Company's Letter Head)

To,

Director
ICMR-National Institute for Research in Bacterial Infections
(Indian Council of Medical Research)
P-33, C.I.T. Road, Scheme-XM, Belehata
P.O. Box 177, Kolkata 700010, INDIA
Ph: +91-33-23633373
Fax: 91-33-23632398

Subject: Submission of Expression of Interest (EoI) for **Joint collaboration in R&D and manufacturing, commercialization of Shigella Vaccine** useful against blood diarrhoea / shigellosis disease.

Ref: ICMR/EoI/..... /202X dated

Sir,

The undersigned having read and examined in detail all the EoI documents pertaining to your transfer of technology, and do hereby express the interest to undertake the research & development/manufacture/ sale /commercialization of the product as mentioned in the EoI document. The details of the Company and contact person are given below:

Name of the Proponent	
Address	
Name, designation & address of the person (to whom all communications shall be made)	
Telephone No. (with STD code)	
Mobile No. of the contact person	
Email ID of the contact person	

The following documents are enclosed:

Sl. No.	Documents required	Type of document attached	Page No.
1	Company Incorporation Certificate from ROC/Partnership deed etc.		

2	GST Registration or GST exemption certificate/ PAN Card.		
3	DCGI/CDSCO license for the existing products available in the market		
4	Certificate from the Chartered Accountant of the Organization/ Audited Balance sheets for las three financial years, Income Tax return.		
5	Proof of a registered office and a manufacturing Unit in India. Including DSIR certificate		
6	GMP / GLC and ISO Certification. Registration copies of both		
7	Authorization Letter	As per format – 2	
8	Undertaking on the Letter Head of the Proponent duly signed & Stamped by Authorized Signatory	As per format – 3	
9	Undertaking on Proponent's Letter Head, duly signed and stamped by the Authorized Signatory	As per format – 4	
10	MSME Certificate (if have any)		
11	Business Plan	A brief concept note on planning & execution, production, marketing etc. (not more than 5 pages)	

I/we hereby declare that my/our EoI is made in good faith and the information contained is true and correct to the best of my/our knowledge and belief.

Thanking you,

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-2

Authorization Letter

(To be submitted on Company's Letter Head)

To,

**Director
ICMR-National Institute for Research in Bacterial Infections
(Indian Council of Medical Research)
P-33, C.I.T. Road, Scheme-XM, Belehata
P.O. Box 177, Kolkata 700010, INDIA
Ph: +91-33-23633373
Fax: 91-33-23632398**

Subject: Letter for Authorized Signatory

Ref: EoI No. ICMR/EoI/..... /202X dated

Sir,

This has reference to your above-mentioned Expression of Interest (EoI) for **Joint collaboration in R&D and manufacturing, commercialization of Shigella Vaccine** useful against blood diarrhoea / shigellosis disease.

Mr./Ms./Mrs./Dr.....is hereby authorized to submit the EoI documents and participate in the processing on behalf of M/s..... (Company Name), who's signature is below.

(Specimen Signature of Representative)

Date:

Place:

Yours faithfully,

(Signature of the Authorized signatory)

Name:.....

Designation:.....

Seal:.....

Format-3

Undertaking with regard to blacklisting
(To be submitted on Company's Letter Head)

To,

Director
ICMR-National Institute for Research in Bacterial Infections
(Indian Council of Medical Research)
P-33, C.I.T. Road, Scheme-XM, Belehata
P.O. Box 177, Kolkata 700010, INDIA
Ph: +91-33-23633373
Fax: 91-33-23632398

Subject: Undertaking regarding Blacklisting / Non-Debarment.

Ref: ICMR/EoI/..... /202X dated.....

Sir,

It is hereby confirmed and declared that M/s..... (Company Name) currently has not been blacklisted / debarred by any Government Department / Public Sector Undertaking / or any other company for which works/assignments/services have been executed / undertaken.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-4

Undertaking with regard to Non-Litigation

(To be submitted on Company's Letter Head)

To,

Director
ICMR-National Institute for Research in Bacterial Infections
(Indian Council of Medical Research)
P-33, C.I.T. Road, Scheme-XM, Belehata
P.O. Box 177, Kolkata 700010, INDIA
Ph: +91-33-23633373
Fax: 91-33-23632398

Subject: Undertaking regarding Litigation.

Ref: ICMR/EoI/..... /202X dated

Sir,

It is hereby confirmed and declared that M/s.....(Company Name) and owner of the firm / board of directors, do not have any litigation / arbitration pending/under trial in court.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-5

Undertaking with regard to laboratory facility

(To be submitted on Company's Letter Head)

To,

Director
ICMR-National Institute for Research in Bacterial Infections
(Indian Council of Medical Research)
P-33, C.I.T. Road, Scheme-XM, Belehata
P.O. Box 177, Kolkata 700010, INDIA
Ph: +91-33-23633373
Fax: 91-33-23632398

Subject: Undertaking regarding laboratory infrastructure.

Ref: ICMR/EoI/..... /202X dated.....

Sir,

It is hereby confirmed and declared that M/s.....(Company Name) do have

- i. Adequate laboratory infrastructure (equipped laboratory facility). Please tick BSL-2/BSL-3/ABSL-3/GMP/GLP/ Other* (if other please specify) and
- ii. Adequate no. of experienced staff/skilled manpower to undertake manufacture/ research/ commercialization of vaccine against blood diarrhoea / shigellosis disease.

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

Format-6

Undertaking with regard to production capacity

(To be submitted on Company's Letter Head)

To,

The Director General,
Indian Council of Medical Research,
Ansari Nagar, New Delhi.

Subject: Undertaking with regard to production capacity.

Ref: ICMR/EoI/..... /202X dated

Sir,

It is hereby confirmed and declared that M/s does have the capacity in all mean (including infrastructure, fund, material, staff etc.) for manufacturing of any previously successful Vaccine (Name of Technology/ Product), minimum..... (mention the quantity per week/per month).

Yours faithfully,

(Signature of the Authorized signatory)

Name:

Designation:

Seal:

Place:

SCHEDULE-A

TECHNOLOGY DETAILS

i. **About the Technology/Product/Process:**

-A Multi-Serotype Outer Membrane Vesicles (MOMV) of shigellae as a novel candidate vaccine

-Novel Shigella vaccine formulation and process to prepare thereof

ii. **Need and utility of the Technology from Public health perspective:**

Shigella, the causative organism of shigellosis, is an antigenically diverse pathogen containing four species (or groups), 50 serotypes and subserotypes; that makes the development of a vaccine challenging. Oral vaccine is pursuing green promise to reduce the burden of disease and mortality caused by enteric pathogen like Shigella. It is generally acknowledged that the protection stimulated by a Shigella vaccine must be broad enough in spectrum to protect against 16 serotypes, including S. dysenteriae 1, all 14 S. flexneri types and S. sonnei. A pentavalent strategy developed at the CVD claimed that 5 Shigella strains (S. sonnei, S. dysenteriae 1, and S. flexneri 2a, 3a, and 6) can collectively provide the necessary broad spectrum protection needed to achieve a vaccine of global utility. Epidemiologically across the world, these are the most important serotypes from the purview of prevalence and disease severity. This strategy is based on the assumption (from analysis of Shigella O antigens and animal cross protection studies) that inclusion of S. dysenteriae 1, S. sonnei, S. boydii, S. flexneri 2a, 3a, and 6 in the vaccine will provide cross protection against the other S. flexneri serotypes because of shared group antigens.

iii. **Technology Readiness level (TRL)**

TLR-4/5

iv. **Validation Status and outcome:**

In-house validation was completed by ICMR -NIRBI. Third party validation was completed by MSD Hilleman laboratories

v. **IP Filing Status/Publications**

PCT filed- PCT/IN2014/000369
